Due to a production error, Supplementary Figures 2,3,5,6,7,8 and 9 were not published. The publisher apologizes for this mistake.
The original version of this article has been updated.
Statements
Supplementary material
The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fimmu.2022.975797/full#supplementary-material
Summary
Keywords
tertiary lymphoid structures, lymphoid neogenesis, tumor mutational burden, cancer immunology, immune checkpoint inhibition, survival, prognosis, tumor microenvironment
Citation
Frontiers Production Office (2022) Erratum: Molecular, Immunological, and Clinical Features Associated With Lymphoid Neogenesis in Muscle Invasive Bladder Cancer. Front. Immunol. 13:975797. doi: 10.3389/fimmu.2022.975797
Received
22 June 2022
Accepted
22 June 2022
Published
04 July 2022
Approved by
Frontiers Editorial Office, Frontiers Media SA, Switzerland
Volume
13 - 2022
Updates
Copyright
© 2022 Frontiers Production Office.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: production.office@frontiersin.org
This article was submitted to Cancer Immunity and Immunotherapy, a section of the journal Frontiers in Immunology
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.